Comparative Pharmacology
Head-to-head clinical analysis: METHYLPHENIDATE versus PEMOLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHYLPHENIDATE versus PEMOLINE.
METHYLPHENIDATE vs PEMOLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylphenidate is a central nervous system (CNS) stimulant that blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their extracellular concentrations. It also acts as a dopamine and norepinephrine releaser. The therapeutic effect in ADHD is thought to be due to increased dopaminergic signaling in the prefrontal cortex.
Pemoline is a central nervous system stimulant that enhances dopaminergic and noradrenergic transmission by blocking the reuptake of dopamine and norepinephrine at the synaptic cleft. It also has mild monoamine oxidase inhibitory activity.
Oral: Initial 5 mg twice daily (before breakfast and lunch), increase by 5-10 mg weekly; usual dose 20-30 mg/day in divided doses; maximum 60 mg/day. Extended-release: 18-36 mg once daily; maximum 72 mg/day.
Oral, 37.5 mg once daily in the morning; may increase by 18.75 mg weekly to a maximum of 112.5 mg/day (divided into 2 doses if total dose > 75 mg).
None Documented
None Documented
Clinical Note
moderateDexmethylphenidate + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Dexmethylphenidate."
Clinical Note
moderateBretylium + Methylphenidate
"Bretylium may decrease the antihypertensive activities of Methylphenidate."
Clinical Note
moderateCyamemazine + Methylphenidate
"The risk or severity of adverse effects can be increased when Cyamemazine is combined with Methylphenidate."
Clinical Note
moderateSulpiride + Methylphenidate
Immediate-release: 2–3 hours; Extended-release: 3–4 hours (drug), 6–8 hours (beaded forms). Context: Short half-life necessitates multiple daily dosing; sustained-release formulations prolong duration.
Terminal elimination half-life is 8-12 hours in children; 12-16 hours in adults. Steady-state is reached within 2-3 days.
Renal: 90% (mostly as metabolites, primarily ritalinic acid), Fecal: <2%, Unchanged drug in urine: ~1%
Pemoline is primarily excreted renally as unchanged drug (40-50%) and metabolites; approximately 20-30% is excreted in feces via biliary elimination.
Category A/B
Category C
CNS Stimulant
CNS Stimulant
"The risk or severity of adverse effects can be increased when Sulpiride is combined with Methylphenidate."